<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684472</url>
  </required_header>
  <id_info>
    <org_study_id>MCART-003</org_study_id>
    <nct_id>NCT04684472</nct_id>
  </id_info>
  <brief_title>Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies</brief_title>
  <official_title>Phase I, Open Label, Study of CXCR4 Modified CD19 CAR-T Therapy in Patients With Relapsed or Refractory CD19+ B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liqun Zou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating&#xD;
      refractory/relapsed B-cell malignancies. CAR-T cells will be investigated as a single agent&#xD;
      both in relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and up to 60% of&#xD;
      patients with B-cell non-Hodgkin's lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>Up to 5 years after modified CD19 CAR-T cells infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days after modified CD19 CAR-T cells infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>B-cell malignancies, Overall response rate(ORR)</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Assessment of ORR(ORR=CR+PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell malignancies, Overall survival</measure>
    <time_frame>Up to 2 years after modified CD19 CAR-T cells infusion</time_frame>
    <description>From the first infusion of modified CD19 CAR-T cells to death or the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell malignancies, progression-free survival（PFS）</measure>
    <time_frame>Up to 2 years after modified CD19 CAR-T cells infusion</time_frame>
    <description>From the first infusion of modified CD19 CAR-T cells to the occurrence of any event, including death, relapse, disease progression, and the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell malignancies, disease control rate (DCR)</measure>
    <time_frame>Month 6,12,18 and 24</time_frame>
    <description>Assessment of DCR(DCR=CR+PR+SD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Leukemia</condition>
  <arm_group>
    <arm_group_label>Modified anti-CD19 CAR T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR T cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Modified anti-CD19 CAR T cells</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Modified anti-CD19 CAR T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18-70 years;&#xD;
&#xD;
          2. Estimated survival time ≥ 12 weeks;&#xD;
&#xD;
          3. Histologically confirmed diagnosis of CD19+ B-ALL or CD19+ B-NHL(meeting one of the&#xD;
             following conditions):&#xD;
&#xD;
               1. Ineffectively or relapses after 2 or more remedial treatments&#xD;
&#xD;
               2. Relapse after auto-HSCT or unsuitable for auto-HSCT;&#xD;
&#xD;
          4. At least one assessable tumor lesion;&#xD;
&#xD;
          5. ECOG performance status 0 to 2;&#xD;
&#xD;
          6. Creatinine clearance rate≥ 60 ml/min, ALT and AST ≤ 2.5 times of upper limit of&#xD;
             normal, total bilirubin ≤ 1.5 times of upper limit of normal;&#xD;
&#xD;
          7. Male and female of reproductive potential must agree to use birth control during the&#xD;
             study and for at least 30 days post study;&#xD;
&#xD;
          8. Patients or their legal guardians volunteer to participate in the study and sign the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other uncontrolled malignancies;&#xD;
&#xD;
          2. Previously treated with any CAR-T cell product or other genetically-modified T cell&#xD;
             therapy;&#xD;
&#xD;
          3. Patients with HIV infection, hepatitis B (HBsAg positive) or hepatitis C（anti-HCV&#xD;
             positive);&#xD;
&#xD;
          4. Patients with central nervous system involvement by lymphoma ,malignant cells in&#xD;
             cerebrospinal fluid or history of brain metastasis;&#xD;
&#xD;
          5. Patients with atrial or ventricular involvement by B-cell malignancies;&#xD;
&#xD;
          6. Patients with tumor mass require urgent treatment, such as ileus or vascular&#xD;
             compression;&#xD;
&#xD;
          7. Patients with severe disease or other uncontrolled diseases that were not suitable for&#xD;
             this trial, such as coronary heart disease, angina pectoris, myocardial infarction,&#xD;
             arrhythmia, cerebral thrombosis, cerebral hemorrhage, grade 2-3 hypertension;&#xD;
&#xD;
          8. Unstable pulmonary embolism, deep venous embolism, or other major arterial/venous&#xD;
             thromboembolism events occurred within 30 days prior to randomization. If patients&#xD;
             receive anticoagulant therapy, the treatment dose must be stable prior to&#xD;
             randomization;&#xD;
&#xD;
          9. Any situations that the investigators believes were not suitable for this trial;&#xD;
&#xD;
         10. Long-term use of immunosuppressive agents after organ transplantation, except for the&#xD;
             patients recently or currently receiving inhaled steroids;&#xD;
&#xD;
         11. Pregnant(or lactation) women;&#xD;
&#xD;
         12. Patients with severe active infections(excluding simple urinary tract infection and&#xD;
             bacterial pharyngitis)within 30 days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Liqun Zou</investigator_full_name>
    <investigator_title>Professor of Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Modified CD19 CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

